Evidence map›Paper›PMID 42196620›Full record

ArticleInternational journal of molecular sciences2026

Exploratory Expression Analysis of Stem Cell and Epithelial-Mesenchymal Transition Markers in Ameloblastoma.

Luis Alberto Martínez-Marcial, Josué Orlando Ramírez-Jarquín, Francisco German Villanueva-Sánchez, Javier Portilla-Robertson, Carla Monserrat Ramírez-Martínez, David Alonso Trejo-Remigio, Claudia Patricia Mejía-Velázquez, Luis Pablo Cruz-Hervert, Luis Fernando Jacinto-Alemán

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Luis Alberto Martínez-MarcialPostgraduate and Research Division, Dentistry School, National Autonomous University of Mexico, Mexico City 04510, Mexico.
Josué Orlando Ramírez-JarquínNeurosciences Division, Cellular Physiology Institute, National Autonomous University of Mexico, Mexico City 04510, Mexico.ORCID 0000-0001-7574-8724
Francisco German Villanueva-SánchezOral and Maxillofacial Pathology, Dental School, ENES-Leon, National Autonomous University of Mexico, Guanajuato 37684, Mexico.
Javier Portilla-RobertsonPostgraduate and Research Division, Dentistry School, National Autonomous University of Mexico, Mexico City 04510, Mexico.ORCID 0000-0002-4924-7376
Carla Monserrat Ramírez-MartínezPostgraduate and Research Division, Dentistry School, National Autonomous University of Mexico, Mexico City 04510, Mexico.
David Alonso Trejo-RemigioPostgraduate and Research Division, Dentistry School, National Autonomous University of Mexico, Mexico City 04510, Mexico.
Claudia Patricia Mejía-VelázquezPostgraduate and Research Division, Dentistry School, National Autonomous University of Mexico, Mexico City 04510, Mexico.
Luis Pablo Cruz-HervertPostgraduate and Research Division, Dentistry School, National Autonomous University of Mexico, Mexico City 04510, Mexico.ORCID 0000-0002-6094-958X
Luis Fernando Jacinto-AlemánPostgraduate and Research Division, Dentistry School, National Autonomous University of Mexico, Mexico City 04510, Mexico.ORCID 0000-0002-0384-5581

Funding

Universidad Nacional Autónoma de México 220726Wellcome Trust 226720
6 · The paper itself

Abstract

Ameloblastoma is a common benign odontogenic tumor. Its etiology has been associated with dysregulation of the MAPK and SHH pathways, and new theories suggest that tumor stem cells (TSCs) and the epithelial-mesenchymal transition (EMT) are participants in their pathogenesis.

objectiveTo determine the immunohistochemical expression of SOX2 and CD44 as indicators of TSCs and the gene expression of vimentin, smooth muscle actin, and MATERIALS AND

methodsConventional, unicystic, and peripheral ameloblastomas and dental follicles, as a control group, were analyzed by peroxidase immunohistochemistry assays for SOX2 and CD44 as TSC-related markers, and the EMT relationship was determined by RT-qPCR expression for vimentin (VIM), alpha smooth muscle actin (ACTA2), fibroblast growth factor receptor 1 (

resultsThe most affected anatomical site was the mandible, with an average age of 38.03 (±20.95) years. SOX2 and CD44 immunoexpression were significantly higher in conventional ameloblastoma. RT-qPCR results showed predominant non-significant expression of VIM, ACTA2, and

conclusionThe significantly higher immunoexpression of SOX2 and CD44 in conventional subtypes could suggest a greater presence of TSCs, and predominant VIM, ACTA2, and

Indexed as

AmeloblastomaBiomarkers, TumorEpithelial-Mesenchymal TransitionJaw NeoplasmsNeoplastic Stem CellsActinsAdultFemaleGene Expression Regulation, NeoplasticHumansHyaluronan ReceptorsImmunohistochemistryMaleMiddle AgedReceptor, Fibroblast Growth Factor, Type 1SOXB1 Transcription FactorsACTA2 protein, humanActinsBiomarkers, TumorCD44 protein, humanFGFR1 protein, humanHyaluronan ReceptorsReceptor, Fibroblast Growth Factor, Type 1SOX2 protein, humanSOXB1 Transcription FactorsVimentinameloblastomaepithelial–mesenchymal transitionimmunohistochemistryRTq-PCRtumor stem cells

Identifiers

PMID42196620
PMCPMC13207394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.